Stock Market & Financial Investment News

News Breaks January 15, 2013 09:00 EDT FRX Forest Labs falls 5.3% Forest Labs is down 5.3%, or $1.99, to $35.60 News For FRX From The Last 14 Days Check below for free stories on FRX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 13, 2013 08:04 EDT FRX Forest Labs' Namenda for Alzheimer's now available in the U.S. Subscribe for More Information 07:17 EDT FRX Forest Labs may be more willing to explore strategic alternatives, says Cantor Cantor believes that Forest may have become more willing to explore strategic alternatives. The firm thinks the company is an attractive takeover candidate. It raised its price target on the shares to $48 from $45 and keeps a Buy rating on the stock. June 12, 2013 06:46 EDT FRX Forest Labs price target raised to $48 from $43 at Jefferies Jefferies expects shares of Forest Labs to continue to trade on the company's strong fundamentals following its agreement with Carl Icahn, but adds the pact could deflate expectations for a potential sale in the near-term. The firm upped its price target for the stock to $48 and keeps a Buy rating on the name. June 11, 2013 08:07 EDT FRX Forest Labs agrees to pact with Icahn, appoints Intrieri to board Subscribe for More Information June 7, 2013 08:05 EDT FRX Forest Labs looks to avoid another fight with Icahn, Reuters reports Forest Laboratories is attempting to avoid another bitter proxy battle with investor Carl Icahn ahead of its annual investor meeting this summer, sources say, reports Reuters. Icahn is Forest's second biggest shareholder and the two sides have been in discussions over the course of the year and talks are ongoing to avoid a third proxy fight in as many years, the sources added. Reference Link June 5, 2013 10:07 EDT FRX On The Fly: Analyst Upgrade Summary Subscribe for More Information 08:23 EDT FRX Forest Labs upgraded to Buy from Hold at Argus Argus upgraded Forest Labs given its diversified product portfolio, future pipeline contribution, and near-term strength from Namenda. Price target is $46. Sign up for a free trial to see the rest of the stories you've been missing.